Presentation is loading. Please wait.

Presentation is loading. Please wait.

Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro.

Published byΦιλύρη Παχής Modified over 5 years ago

Similar presentations

Presentation on theme: "Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro."— Presentation transcript:

1 Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures  Giovanni Ruvolo, Sc.D., Liana Bosco, Ph.D., Antonina Pane, M.D., Giovanni Morici, Ettore Cittadini, M.D., Maria C. Roccheri, Sc.D.  Fertility and Sterility  Volume 87, Issue 3, Pages (March 2007) DOI: /j.fertnstert Copyright © 2007 American Society for Reproductive Medicine Terms and Conditions

2 FIGURE 1 Flow chart of studied patients.
Ruvolo. Apoptosis in human cumulus cells. Fertil Steril 2007. Fertility and Sterility  , DOI: ( /j.fertnstert ) Copyright © 2007 American Society for Reproductive Medicine Terms and Conditions

Download ppt "Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro."

Similar presentations

Age at menarche: a predictor of diminished ovarian function?

Age at menarche: a predictor of diminished ovarian function?
Risks of tubo-ovarian abscess in cases of endometrioma and assisted reproductive technologies are both under- and overreported  Claire Villette, M.D.,

Risks of tubo-ovarian abscess in cases of endometrioma and assisted reproductive technologies are both under- and overreported  Claire Villette, M.D.,
Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration  Jean-noêl Hugues,

Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration  Jean-noêl Hugues,
Keri Greenseid, M. D. , Sangita Jindal, Ph. D. , Athena Zapantis, B. S

Keri Greenseid, M. D. , Sangita Jindal, Ph. D. , Athena Zapantis, B. S
Daily physical activity and hot flashes in the Study of Women's Health Across the Nation (SWAN) Flashes Study  Carolyn Gibson, M.P.H., M.S., Karen Matthews,

Daily physical activity and hot flashes in the Study of Women's Health Across the Nation (SWAN) Flashes Study  Carolyn Gibson, M.P.H., M.S., Karen Matthews,
Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation.

Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation.
Christine Jablonski, M. D. , Marco Alifano, M. D

Christine Jablonski, M. D. , Marco Alifano, M. D
The great debate: varicocele treatment and impact on fertility

The great debate: varicocele treatment and impact on fertility
Fertility and Sterility  Volume 97, Issue 3, Pages (March 2012)

Fertility and Sterility  Volume 97, Issue 3, Pages (March 2012)
The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition  Lorraine Dennerstein,

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition  Lorraine Dennerstein,
Fernando Zegers-Hochschild, M.D.  Fertility and Sterility 

Fernando Zegers-Hochschild, M.D.  Fertility and Sterility 
Michael M. Alper, M.D.  Fertility and Sterility 

Michael M. Alper, M.D.  Fertility and Sterility 
Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization.

Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization.
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials  Ana Cobo, Ph.D., César Diaz, M.D. 

Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials  Ana Cobo, Ph.D., César Diaz, M.D. 
Hepatitis and reproduction

Hepatitis and reproduction
The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.

The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.
Ovarian pregnancy after in vitro fertilization

Ovarian pregnancy after in vitro fertilization
Robot-assisted laparoscopy for infertility treatment: current views

Robot-assisted laparoscopy for infertility treatment: current views
Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women  Carlos Iglesias, M.D., Manish Banker, M.D.,

Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women  Carlos Iglesias, M.D., Manish Banker, M.D.,

Similar presentations

Ads by Google